Navigation Links
CytRx Announces Positive Results of Arimoclomol in Preclinical,Stroke Recovery Studies

to be safe and well-tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS, also known as Lou Gehrig's disease. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the second half of 2007, subject to U.S. Food and Drug Administration (FDA) approval. The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS and has also been granted orphan medicinal product status for the treatment of ALS by the European Commission. For more information, visit www.cytrx.com.

Worcester, Massachusetts based RXi Pharmaceuticals Corporation is a biopharmaceutical research and development company that will focus on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus will be on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chemistry and RNAi delivery. The company was founded by CytRx and RNAi pioneers Craig Mello, Ph.D., 2006 Nobel Laureate for discovering RNAi and inventing RNAi therapeutics, Tariq M. Rana, Ph.D., inventor of fundamental technology for stabilizing RNAi and of RNAi nanotransporters, Greg Hannon, Ph.D., discoverer of RNAi mechanism (RISC) and short hairpin RNAi (shRNAi), and Michael Czech, Ph.D., a leader in the application of RNAi to diabetes and obesity. RXi's CEO, Tod Woolf, Ph.D., previously co-invented and commercialized STEALTH(TM) RNAi, one of the most widely used second-generation RNAi research products.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
3. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:6/2/2015)... 2015 The Canadian Society for Vascular Surgery (CSVS) ... or procedures that are commonly ordered but not ... Choosing Wisely Canada.  The list identifies five (5) ... patients and physicians about what care is really ... Surgery,s list identified the following five (5) recommendations: ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ) ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... Surgical Incision Closures in US$ Million by the following Product ...
(Date:6/2/2015)... RALEIGH, N.C. , June 2, 2015 BioDelivery ... to weather conditions, the presentation by Dr. Mark A. ... been changed to 2:30 PM Eastern time. Jefferies ... Time Grand Hyatt, New York City ... and can be accessed at www.bdsi.com .  For those ...
Breaking Medicine Technology:As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4Surgical Incision Closures - Global Strategic Business Report 2015 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 3
... Benefit over Placebo Larger at One Year than ... 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that ... Phase 2 study in mild-to- moderate Alzheimer's,disease were ... months. Importantly, on every endpoint studied, the benefits,of ...
... Study Presented at Federation of,Clinical Immunology Societies ... 11, 2007 /PRNewswire-FirstCall/ --,Orchestra Therapeutics, Inc. (Bulletin ... its completed Phase II open-label study of,NeuroVax(TM), ... for the treatment of relapsing-remitting multiple sclerosis,(MS). ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Acne is ... (“bacne”) can be particularly stubborn to eliminate and hard to ... most common in teens and young adults, in the years ... produce sebum, or oil,” says Jayme Bashian, director and lead ... characteristic pimples, blackheads and cysts of acne are caused by ...
(Date:6/3/2015)... 03, 2015 Fourroux Prosthetics, located at ... will celebrate its grand opening with a ribbon cutting ... prosthetic center of its kind in the area, Fourroux ... care and outcomes through use of patented advanced prosthetics ... CEO of Fourroux Prosthetics, states, “Our goal has always ...
(Date:6/3/2015)... Implant design can have a profound influence on ... to an implant surface. The unique triangular-shape of the ... bone regeneration, resulting in the gain of greater volume ... for more esthetic restorations. , “It’s all in the ... The triangular neck of the V3 provides solid anchorage ...
(Date:6/3/2015)... These are challenging and unpredictable times ... number of digital-first business are rewriting the rules for ... serious need for traditional businesses to take on a ... deliver their services. On top of this there ... technology start-ups, to bring new innovation and approaches to ...
(Date:6/3/2015)... DailyEndorphin is pleased to announce the launch ... this highly configurable new offering, DE's annual clients may ... of its wellness programming for the entire year as ... this new module, annual clients may also do the ... surveys, (3) Continually report on participant progress towards the ...
Breaking Medicine News(10 mins):Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:MIS Implants Launches Radically New V3 Dental Implant For Immediate Biological Benefits 2Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:DailyEndorphin Launches Wellness "Events" Portal 2
... in the March 2006 issue of Archives of Ophthalmology says ... risk of relapse of a vision-threatening eyelid condition called trichiasis.// ... clinical trial funded by the National Eye Institute (NEI), part ... ,It was found that azithromycin was better than the local ...
... Medicine in St. Louis say that a noninvasive approach ... developing drugs for cystic fibrosis and pneumonia. // Positron ... induced inflammation in the lungs of healthy volunteers. ... a new drug decreased lung inflammation, the options for ...
... you can’t wait for a appointment a local clinic now ... clear results in 10 minutes//, ,Chlamydia is the most ... no symptoms, and can be passed on to others without ... including problems in pregnancy and infertility in both men and ...
... long term will make the brain to lose its ability, gradually ... led by Lambros Messinis at the University Hospital of Patras in ... taken marijuana heavily. They smoked at least four joints a week ... New Scientist. ,Their brains were rustier than those ...
... is found to improve their kidney function in patients with heart ... he said that those patients who took 80 mg of the ... ,The drug is the world's top-selling prescription drug. The data of ... scientific meeting in Atlanta. ,50% of the patients, who ...
... Jordan said that the kingdom was untouched by the avian flu ... the joint effort of both the public and the government. He ... in the country. , The minister made the ... , In that occasion to celebrate this great achievement the ...
Cached Medicine News:Health News:Home Chlamydia Test 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: